Europe Drug Delivery Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Inhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), By Application (Treatment Of Diseases, Research/Academic Purposes), And By Geography - Forecasts From 2022 To 2027

Published:  Mar 2022 Report Code: KSI061612580 Pages: 100

The Europe Drug Delivery Market is expected to grow at a compound annual growth rate of 6.44% over the forecast period to reach a market size of US$282.182 billion in 2027, from US$182.316 billion in 2020.

Drug delivery refers to a process of transferring drugs or therapeutic chemicals into the human body either manually or through the drug delivery systems via nasal, oral, or skin contact. Increasing public spending on healthcare, expanding research and development, advancing technology, growing age-related diseases, and rising prevalence of chronic diseases are some drivers for the European drug delivery market.

Besides that, increasing biologics markets are also the key contributor to the growing European drug delivery market. Biologics is a special and powerful drug used to slow down or stop damaging inflammation. The growth in the Biologics market can be witnessed through the example of Evonik recently acquiring the RESOMER platform to increase its market share in the segment.  The significant challenge to the growth of this industry is the increasing pricing pressure, mainly due to high research costs attributed to drug development.  

Increase in Chronic and Infectious Diseases:

The increase in chronic and infectious diseases is one of the primary drivers of the European drug delivery market. In addition to Europe’s Cancer Beating Plan, the European Commission is also working on the key areas of cardiovascular diseases, diabetes, mental health, neurological disorders, and chronic respiratory diseases that are the major causes of death in Europe. The increasing chronic diseases have given rise to a new delivery system, CRDDS (Controlled Release Drug Delivery System), a reliable method that uses an appropriate amount of drug dosage and releases it in a predetermined area.

Infectious diseases have witnessed a sudden outbreak and are emerging at a rate never seen before. In the last 5-6 decades, the world has witnessed contagious diseases like SARS, Ebola, Swine Flu, MERS, Zika, chikungunya, and recently COVID-19, which has brought in the need to introduce more disease-specific drugs to the market. With history kept in mind, the outbreak of diseases in the future needs to be overpowered by a strong drug-delivering market in the coming years.

Increasing Research and Development to play a key role in European Drug Delivery Market:

Research and development, although is a time-consuming and costly process, is expected to play a key role in the development of the European drug market. Companies like Pfizer, Bayer AG, etc., are known to have been engaged in severe research projects and, as a result, have added substantially to the scientific knowledge and medical technology advancements in the drug market. For instance, Pfizer’s development of Molecular glues that can hijack the body’s garbage disposable system is expected to become a different drug paradigm as it can open several possibilities, especially when it shows a great promise for transcription factors that are very difficult to target.

Impact of COVID-19 Pandemic on the Europe Drug Delivery Market:

With the outbreak of the COVID pandemic, the European drug-delivering market witnessed a loss initially. As per European Pharmaceutical Review, an outbreak of COVID 19 was followed by fewer walk-ins in drug retail shops which brought about a loss in profit. Later, when the market witnessed a surge in the demand or panic buying for chronic disorder pharmaceuticals, which increased the demand by 9%, the supply shortage made it difficult to fulfill the demand chain that became a serious concern and burden for the healthcare sector. In the first wave, along with the decline of non-essential surgeries, the demand for treatments also dropped, which negatively impacted the market.

Nevertheless, this initial hit was almost fully compensated till the second wave in Europe, when the production of the pharmaceutical sector increased significantly.  As per the Policy Department for Economic, Scientific, and Quality of Life Policies, the retail in pharmaceutical increased by 12% as compared to April, which implies that until September, the drug and pharmaceutical sector recovered by 98%.

With the increasing AI, huge investments in research and development, and technological advancement, especially in the COVID vaccines, the European drug and pharmaceutical sector is experiencing significant growth in the coming years. For instance, Pfizer and MPP are ready to enable access to oral antiviral treatment in 95 countries.

Europe Drug Delivery Market Scope:

Report Metric Details
 Market size value in 2020  US$182.316 billion
 Market size value in 2027  US$282.182 billion
 Growth Rate  CAGR of 6.44% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Application, And Geography
 Regions covered  U.K., Germany, Switzerland, France, Spain, Italy, Others
 Companies covered  Ascendis Pharma A/S, Pfizer Inc., Becton, Dickinson Company, Baxter   International Inc., Novartis, Bayer AG, Antares Pharma, Roche Holding
 Customization scope  Free report customization with purchase



  • By Type
    • Inhalation Drug Delivery
    • Injectable Drug Delivery
    • Nasal Drug Delivery
    • Oral Drug Delivery
    • Transdermal Drug Delivery
  • By Application
    • Treatment of diseases
    • Research/Academic purposes
  • By Geography
    • U.K.
    • Germany
    • Switzerland
    • France
    • Spain
    • Italy
    • Others

1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Inhalation Drug Delivery
5.3. Injectable Drug Delivery
5.4. Nasal Drug Delivery
5.5. Oral Drug Delivery
5.6. Transdermal Drug Delivery

6.1. Treatment of diseases
6.2. Research/Academic purposes

7.1. Introduction
7.2. U.K.
7.3. Germany
7.4. Switzerland
7.5. France
7.6. Spain
7.7. Italy
7.8. Others

8.1. Major Players and Strategy Analysis
8.2.  Emerging Players and Market Lucrativeness
8.3.  Mergers, Acquisitions, Agreements, and Collaborations
8.4.  Vendor Competitiveness Matrix

9.1. Ascendis Pharma A/S
9.2. Pfizer Inc.
9.3. Becton, Dickinson Company
9.4. Baxter International Inc.
9.5. Novartis
9.6. Bayer AG
9.7. Antares Pharma
9.8. Roche Holding AG

Ascendis Pharma A/S

Pfizer Inc.

Becton, Dickinson Company

Baxter International Inc.


Bayer AG

Antares Pharma

Roche Holding


Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


We are in compliance with the global privacy laws.

Connect With Us